PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2021.7642022543803-816Clinical Efficacy of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer Patients with Liver Metastases: A Network Meta-Analysis of Nine Randomized Controlled TrialsQing Yin, Longguo Dai, Ruizhu Sun, Ping Ke, Liya Liu, Bo Jianghttp://e-crt.org/upload/pdf/crt-2021-764.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2021.764, http://e-crt.org/upload/pdf/crt-2021-764.pdf
Frontiers in Pharmacology10.3389/fphar.2021.686876202112Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer: A Network Meta-Analysis of Randomized Clinical TrialsWeidong Zhang, Jingjing Gu, Chunming Bian, Guanhong Huanghttps://www.frontiersin.org/articles/10.3389/fphar.2021.686876/full
Cancer Management and Research10.2147/cmar.s1885512019Volume 111623-1629<p>Complete response associated with immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis of nine randomized controlled trials</p>Jie Li, Qi He, Xiu Yu, Khalid Khan, Xuanwen Weng, Minjie Guanhttps://www.dovepress.com/getfile.php?fileID=48122, https://www.dovepress.com/getfile.php?fileID=48122
Cancer Immunology, Immunotherapy10.1007/s00262-022-03140-520227192239-2254Severe immune-related adverse events of immune checkpoint inhibitors for advanced non-small cell lung cancer: a network meta-analysis of randomized clinical trialsJingjing Gu, Lei Shi, Xiaowen Jiang, Jianhua Wen, Xiaoming Zheng, Hu Cai, Weidong Zhanghttps://link.springer.com/content/pdf/10.1007/s00262-022-03140-5.pdf, https://link.springer.com/article/10.1007/s00262-022-03140-5/fulltext.html, https://link.springer.com/content/pdf/10.1007/s00262-022-03140-5.pdf
International Immunopharmacology10.1016/j.intimp.2020.106907202088106907Sarcopenia affects clinical efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients: A systematic review and meta-analysisJiajun Wang, Liu Cao, Shun Xuhttps://api.elsevier.com/content/article/PII:S1567576920319950?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1567576920319950?httpAccept=text/plain
Clinical Lung Cancer10.1016/j.cllc.2011.08.0052012132107-114Efficacy of EGFR Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer: A Meta-Analysis of 13 Randomized TrialsFausto Petrelli, Karen Borgonovo, Mary Cabiddu, Sandro Barnihttps://api.elsevier.com/content/article/PII:S1525730411002105?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1525730411002105?httpAccept=text/plain
Journal of Cancer Research and Clinical Oncology10.1007/s00432-019-03104-w20191463777-785The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastasesRui Kitadai, Yusuke Okuma, Taiki Hakozaki, Yukio Hosomihttp://link.springer.com/content/pdf/10.1007/s00432-019-03104-w.pdf, http://link.springer.com/article/10.1007/s00432-019-03104-w/fulltext.html, http://link.springer.com/content/pdf/10.1007/s00432-019-03104-w.pdf
Disease Markers10.1155/2022/2631852202220221-11The Efficacy of Immune Checkpoint Inhibitors vs. Chemotherapy for KRAS-Mutant or EGFR-Mutant Non-Small-Cell Lung Cancers: A Meta-Analysis Based on Randomized Controlled TrialsWei Chen, Ling Li, Sheng Cheng, Junxian Yuhttp://downloads.hindawi.com/journals/dm/2022/2631852.pdf, http://downloads.hindawi.com/journals/dm/2022/2631852.xml, http://downloads.hindawi.com/journals/dm/2022/2631852.pdf
Thoracic Cancer10.1111/1759-7714.148422023Safety evaluation of immune checkpoint inhibitors combined with chemotherapy for the treatment of small cell lung cancer: A meta‐analysis of randomized controlled trialsVito Longo, Alessandro Rizzo, Annamaria Catino, Michele Montrone, Domenico Galettahttps://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.14842, https://onlinelibrary.wiley.com/doi/full-xml/10.1111/1759-7714.14842, https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.14842
10.21203/rs.3.rs-248839/v12021Immune-related adverse events associated with PD-1/PD-L1 Inhibitors used as first-line treatment for advanced non-small cell lung cancer: a Bayesian network meta-analysis of randomized clinical trialsJingjing Gu, Weidong Zhang, Chunming Bian, Guanhong Huanghttps://www.researchsquare.com/article/rs-248839/v1, https://www.researchsquare.com/article/rs-248839/v1.html